Movement Disorders D009069

Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Movement Disorders

Description

Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.   MeSH

Hierarchy View

Subtype Terms (11)

Akathisia, Drug-Induced
3 drugs (2 approved, 1 experimental)

Angelman Syndrome
12 drugs (5 approved, 7 experimental)

Dyskinesias
22 drugs (13 approved, 9 experimental)

Dystonic Disorders
7 drugs (5 approved, 2 experimental)

Essential Tremor
32 drugs (17 approved, 15 experimental)

Hepatolenticular Degeneration
21 drugs (10 approved, 11 experimental)

Multiple System Atrophy
53 drugs (35 approved, 18 experimental)

Pantothenate Kinase-Associated Neurodegeneration
2 drugs (1 approved, 1 experimental)

Parkinsonian Disorders
32 drugs (16 approved, 16 experimental)

Supranuclear Palsy, Progressive
47 drugs (20 approved, 27 experimental)

Tic Disorders
13 drugs (7 approved, 6 experimental)


Approved Indicated Drugs (2)

Other Experimental Indicated Drugs (1)


Organization Involved with Phase 4 Indications (2)

Organization Involved with Phase 3 Indications (3)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.